Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764415 | 0.86 | NPC1 (0.35) | NPC1HRH3CARM1PRMT6TMEM97 | |
| SCHEMBL25123461 | 0.85 | HRH3 (0.33) | NPC1HRH3CARM1PRMT6HTR1B | |
| SCHEMBL24673656 | 0.85 | HRH3 (0.33) | NPC1HRH3CARM1PRMT6HTR1B | |
| SCHEMBL22848886 | 0.85 | HRH3 (0.38) | NPC1HRH3CARM1PRMT6MEN1 | |
| SCHEMBL23945992 | 0.84 | NPC1 (0.40) | NPC1HRH3CARM1PRMT6TMEM97 | |
| SCHEMBL23568258 | 0.83 | NPC1 (0.37) | NPC1HRH3CARM1PRMT6ADRB2 | |
| SCHEMBL26408395 | 0.82 | HRH3 (0.35) | NPC1HRH3CARM1PRMT6MEN1 | |
| SCHEMBL24764431 | 0.82 | NPC1 (0.34) | NPC1HRH3CARM1PRMT6TMEM97 | |
| SCHEMBL27425335 | 0.81 | HRH3 (0.37) | HRH3 | |
| SCHEMBL23560109 | 0.81 | HRH3 (0.37) | NPC1HRH3CARM1PRMT6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885HRH3 3631/4885CARM1 824/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885HRH3 3631/4885CARM1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.